Source: Brazilian Journal of Cardiovascular Surgery. Unidade: FMRP
Subjects: PROCEDIMENTOS CIRÚRGICOS CARDÍACOS, HIPOTENSÃO, AZUL DE METILENO, FARMACOTERAPIA
ABNT
EVORA, Paulo Roberto Barbosa et al. After thirty years, we still cannot understand why methylene blue is not a reference to treat vasoplegic syndrome in cardiac surgery. Brazilian Journal of Cardiovascular Surgery, v. 36, n. 3, p. 406-411, 2021Tradução . . Disponível em: https://doi.org/10.21470/1678-9741-2021-0955. Acesso em: 14 ago. 2024.APA
Evora, P. R. B., Soares, R. O. dos S., Bassetto, S., Martins, M. A., Silva, F. L. da, & Basile-Filho, A. (2021). After thirty years, we still cannot understand why methylene blue is not a reference to treat vasoplegic syndrome in cardiac surgery. Brazilian Journal of Cardiovascular Surgery, 36( 3), 406-411. doi:10.21470/1678-9741-2021-0955NLM
Evora PRB, Soares RO dos S, Bassetto S, Martins MA, Silva FL da, Basile-Filho A. After thirty years, we still cannot understand why methylene blue is not a reference to treat vasoplegic syndrome in cardiac surgery [Internet]. Brazilian Journal of Cardiovascular Surgery. 2021 ; 36( 3): 406-411.[citado 2024 ago. 14 ] Available from: https://doi.org/10.21470/1678-9741-2021-0955Vancouver
Evora PRB, Soares RO dos S, Bassetto S, Martins MA, Silva FL da, Basile-Filho A. After thirty years, we still cannot understand why methylene blue is not a reference to treat vasoplegic syndrome in cardiac surgery [Internet]. Brazilian Journal of Cardiovascular Surgery. 2021 ; 36( 3): 406-411.[citado 2024 ago. 14 ] Available from: https://doi.org/10.21470/1678-9741-2021-0955